In all areas of our work, honor is the guiding principle and the foundation for realizing our mission.
Natalie, 10, GRIN2B Patient
We are neuroscience innovators.
Neurvati Neurosciences is uniquely positioned to identify, acquire, and develop potential therapies targeting a range of neurological and psychiatric disorders. We have an unmatched ability to assess advances in neuroscience research, review pre-clinical and clinical data, understand regulatory needs and confirm the commercial potential of promising product candidates.
As a Blackstone Life Sciences portfolio company, Neurvati is powered by best-in-class expertise, relentless passion, and extensive resources that allow us to optimize the development of neuroscience therapies. To fuel our success, we engage with strategic partners including other global leaders in neuroscience research and product development. We also align ourselves closely with the patient communities we serve. These efforts bring us the insights and experience necessary to support our efforts to deliver drugs with the potential to transform the lives of patients.
We are creative partners in neuroscience drug development
The Neurvati business model is structured to meet the demands associated with neuroscience drug development and commercialization. We maintain a long-term, strategic view of the neuroscience ecosystem and have the ability to apply customized business structures and strategies to advance our programs, including establishing fit-for-purpose subsidiary companies. Our deep base of resources allows us to achieve the highest levels of business versatility and operational productivity.
As the first example of our business strategy in action, in 2021 Neurvati established GRIN Therapeutics to advance a targeted approach to the treatment of GRIN-related disorders and other types of pediatric epilepsy.
The Neurvati leadership team has deep expertise in neuroscience research and in all phases of drug development and commercialization, backed by worldwide industry connections and a shared dedication to meeting the needs of the patient communities we serve.
Board of Directors
Neurvati: Built for Success
Backed by the financial and professional resources of Blackstone Life Sciences, a division of Blackstone, the world’s largest alternative asset manager, Neurvati Neurosciences is ideally structured to advance drug candidates through near- and long-term clinical and regulatory milestones. Our operational capabilities and global reach and resources empower us to achieve levels of business agility and superior clinical execution that represent significant competitive advantages.
For additional information, please contact us using the form below.